Mydecine Innovations Group Inc.

CNSX: MYCO


Canadian symbol: MYCO.CN
US symbol: MYCOF


mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.




Company News Date
MYCO.CN
Mydecine Innovations Group
1 week ago
MYCO.CN
Mydecine Innovations Group
3 weeks ago
MYCO.CN
Mydecine Innovations Group
2 months ago
MYCO.CN
Mydecine Innovations Group
2 months ago
MYCO.CN
Mydecine Innovations Group
2 months ago
MYCO.CN
Mydecine Innovations Group
3 months ago
MYCO.CN
Mydecine Innovations Group
3 months ago
MYCO.CN
Mydecine Innovations Group
3 months ago
MYCO.CN
Mydecine Innovations Group
5 months ago
MYCO.CN
Mydecine Innovations Group
5 months ago
MYCO.CN
Mydecine Innovations Group
6 months ago
MYCO.CN
Mydecine Innovations Group
7 months ago
MYCO.CN
Mydecine Innovations Group
7 months ago
MYCO.CN
Mydecine Innovations Group
7 months ago
MYCO.CN
Mydecine Innovations Group
8 months ago
MYCO.CN
Mydecine Innovations Group
8 months ago
MYCO.CN
Mydecine Innovations Group
8 months ago
MYCO.CN
Mydecine Innovations Group
8 months ago
MYCO.CN
Mydecine Innovations Group
9 months ago
MYCO.CN
Mydecine Innovations Group
9 months ago
MYCO.CN
Mydecine Innovations Group
9 months ago
MYCO.CN
Mydecine Innovations Group
9 months ago
MYCO.CN
Mydecine Innovations Group
9 months ago
MYCO.CN
Mydecine Innovations Group
10 months ago
MYCO.CN
Mydecine Innovations Group
10 months ago
MYCO.CN
Mydecine Innovations Group
11 months ago
MYCO.CN
Mydecine Innovations Group
11 months ago
MYCO.CN
Mydecine Innovations Group
11 months ago
MYCO.CN
Mydecine Innovations Group
11 months ago
MYCO.CN
Mydecine Innovations Group
12 months ago
MYCO.CN
Mydecine Innovations Group
12 months ago
MYCO.CN
Mydecine Innovations Group
12 months ago
MYCO.CN
Mydecine Innovations Group
12 months ago
MYCO.CN
Mydecine Innovations Group
1 year ago
MYCO.CN
Mydecine Innovations Group
1 year ago
MYCO.CN
Mydecine Innovations Group
1 year ago
MYCO.CN
Mydecine Innovations Group
1 year ago



Insiders transactions are updated every hour.
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by Mydecine Innovations Group Inc.


Mydecine Fully Completes the First-Ever International Export of Psilocybin Mushrooms and Solidifies its Clinical and Commercial Supply Chain

DENVER, March 01, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma company in the life sciences category committed to the research and development, production, and acceptance of alternative nature-sourced medicine for mainstream use, has completed the world’s firs... Read More...

Kognitiv Corporation accelerates Platform-as-a-Service capabilities with key hires

Lin Classon and Jisun Hahn join collaborative commerce firmTORONTO, Feb. 23, 2021 - Kognitiv Corporation, a global leader in the rapidly expanding market for collaborative commerce, continues to make senior strategic hires across its Client and Product teams with the announcement of Jisun Hahn as SVP, Global Head of Industry Solutions and... Read More...

2021 LG Gram Laptops Bring Larger Screens, Sleek Design and New 2-in-1 Model to Canada

VANCOUVER, BC, Jan. 14, 2021 - Trading resumes in:Company: Mydecine Innovations Group Inc.CSE Symbol: MYCOAll Issues: OuiResumption (ET): 12:00 PMIIROC can make a decision to impose a temporary suspension (halt) of trading in a security of a publicly-listed company. Trading halts are implemented to ensure a fair and orderly market. IIROC ... Read More...

Mydecine Innovations Group Sponsors Study on Neuron Level Response to Psilocybin at University of Maryland

DENVER, Jan. 28, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...

Mydecine Innovations Group Files Preliminary Prospectus in Connection with Bought Deal Offering of Units

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATESMydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for ma... Read More...

Mydecine Innovations Group Announces C$10 Million Bought Deal Offering of Units

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/DENVER, Jan. 14, 2021 - Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine" or the "Company'), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative natu... Read More...

Mydecine Innovations Group Appoints Gordon Neal to Board of Directors and Dean Ditto as Chief Financial Officer

MYCO Continues to Strengthen Board of Directors in Anticipation of Senior Exchange Listing RequirementsDENVER, Jan. 11, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative ... Read More...

Mydecine Innovations Group Sponsors First Lab-Based Study of Established Microdosers at Macquarie University in Australia

DENVER, Jan. 05, 2021 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it is sponsoring a study titled... Read More...

Mydecine Innovations Group Engages ethica CRO as Contract Research Organization Partner for Phase 2A PTSD Clinical Trials

DENVER, Dec. 21, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced that it has engaged ethica CRO ("ethica CRO"), a full-servic... Read More...

Mydecine Innovations Group Engages the ProPharma Group to Proceed with FDA Filings and Approval for Novel Research and Multiple Phase Clinical Trials

Leading FDA consultancy firm to advise on drug development and clinical trial pipelineDENVER, Dec. 15, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic m... Read More...

Mydecine Innovations Group to Make First Commercial Export of Legal Psilocybin Mushrooms

Mydecine completes harvest and is preparing to export 20 kilograms of psilocybin mushrooms from Jamaica to Canada for increased global supply scale of cGMP nature-sourced psilocybinDENVER, Dec. 08, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company com... Read More...

Mydecine Innovations Group Offers Management and Clinical Trials Update

Dr. Rakesh Jetly Appointed Chief Medical OfficerCompany Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in VeteransVANCOUVER, British Columbia, Nov. 17, 2020 -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (“Mydecine” or the “Company’), an emerging biopharma and life... Read More...

Mydecine Innovations Group Appoints Boustead Capital Markets LLP as Financial Advisor for its Planned Dual Listing on the London Stock Exchange

VANCOUVER, British Columbia, Oct. 19, 2020 -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead”) to commence the dual listing process on the London Stock Exchange (“LSE” or the “Exchange”) for the ... Read More...

Mydecine Innovations Group subsidiary NeuroPharm Engages FreeMind Group to Access Non-Dilutive Global Funding Opportunities

VANCOUVER, British Columbia, Oct. 14, 2020 -- NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding opportunities globally.NeuroPharm™ is developing a unique... Read More...

Mydecine Innovations Group Announces Filing of Provisional Patent for the Treatment of PTSD with Psilocybin

VANCOUVER, British Columbia, Oct. 07, 2020 -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) covering composition of mat... Read More...

Mydecine Innovations Group Announces The Official Mindleap Health Mobile App Launch in IOS and Android Stores Today

Picture 1Figure 1Figure 1DENVER, Sept. 30, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine") is pleased to announce that its subsidiary Mindleap Health (“Mindleap”), a digital telehealth mobile application for mental coaching and wellbeing, has officially launched and is available for download today:... Read More...

Mindleap Health Announces The Launch of The World’s First Telehealth Platform For Psychedelic Integration

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/42c4893d-6232-4d13-9d58-b3098cc222bbDENVER, Sept. 24, 2020 --  Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that its subsidiary Mindleap Health’s (“Mindleap” ) telehealth platform wil... Read More...

Mindleap Health Implements HIPAA Compliance Standards and Appoints Former Canadian Ministry of Health Telemedicine Expert as Head of Program Management

DENVER, Sept. 17, 2020 -- Mydecine Innovations Group, Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) ("Mydecine"), is pleased to announce that its wholly-owned subsidiary, Mindleap Health (“Mindleap”), has implemented a comprehensive information security rollout of next-generation cyber-security solutions to meet HIPAA compliance standards. Mi... Read More...

Mydecine Innovations Group, Inc. to Create Special Committee for the Spin Out of US Related Assets

DENVER, Sept. 15, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine"), today announced the Company has formed a special committee to evaluate a number of options to increase shareholders value.Topics that the special committee will discuss include, but limited to, a potential spin out of certain company ... Read More...

Mydecine Innovations Group Would Like to Give Thanks to its Shareholders for Extending the Lockup on the Five Cent Placement for Another 120 Days

DENVER, Sept. 03, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine", “MIG”) is pleased to announce that its shareholders have agreed to extend lock-up restrictions in respect to 35,737,460 shares of the Company that were due to be released on September 6, 2020, for an additional 120 days.Under the ter... Read More...

Mydecine™ Launches World’s First Natural-Sourced cGMP Psilocybin for Global Research, Sales, and Distribution Enterprise

Being Facilitated Under a Schedule 1 Health Canada Dealer’s LicenseDENVER, Aug. 18, 2020 -- Mydecine Innovations Group, Inc., (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine™") is pleased to announce it is the first organization to exercise its cGMP(₁) capabilities under a special license to legally produce, transfer, sell, and export pharma... Read More...

Mydecine Innovations Group Featured in Forbes for the First-Of-Its-Kind Clinicals Using Psilocybin Therapy For PTSD

DENVER, Aug. 13, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine"), is pleased to announce that NeuroPharm Inc., a company focused on developing unique mental health therapies and approaches for veteran wellness, was recently covered in Forbes for its ground-breaking psilocybin clinical trials for trea... Read More...

Mydecine Innovations Group Provides Inaugural Corporate Update in the Expanding Psychedelic Medicines Sector

DENVER, Aug. 12, 2020 -- Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) ("Mydecine" “MIG”), is pleased to provide a corporate update regarding recent advancements and achievements that continues to add shareholder value and position Mydecine as a genuine leader in the ever-expanding fungi and psychedelic sectors. Throug... Read More...

Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness

DENVER, Aug. 04, 2020 -- Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform.Mindleap™... Read More...

Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

DENVER , July 16, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that, further to its press release of July 14, 2020 , its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental heal... Read More...

Mydecine Innovations Group Inc. Signs Definitive Agreement for Acquisition of NeuroPharm Inc. Positioned as a Leader in the Development of Psychedelic Treatments for the Betterment of Veterans

DENVER , July 14, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that, further to its press release on June 10, 2020 , it has entered into a definitive share exchange agreement (the "Share Exchange Agreement") for the acquisition (the " Acquisition ") of 100% of NeuroPharm Inc. ("Neu... Read More...

Mydecine Innovations Group Adds World Renowned, 7-Time Nobel Peace Prize Nominee Dr. M.S Reddy to its Scientific Advisory Board

VANCOUVER, British Columbia , July 7, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), announced today that seven-time Nobel Prize-nominated scientist Dr. Malireddy Srinivasulu Reddy will be joining the Mydecine team as a Scientific Advisor.Dr. Reddy is one of the world's most pre-eminent authorities in appl... Read More...

Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board

VANCOUVER, British Columbia , June 30, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine"), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board.Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and researc... Read More...

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

VANCOUVER, British Columbia, June 23, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (MYCOF) (0NF.F) ("Mydecine") is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee.The new members of the science team will provide scientific expertise and corporate strategy support as Mydeci... Read More...

Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform

VANCOUVER, British Columbia , June 17, 2020 -- Mydecine Innovations Group Inc. (formerly New Leaf Brands Inc.) (MYCO.CN) (OTCMKTS:MYCOF) (FSE: 0NF) ("Mydecine") is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. ("Mindleap") for the acquisition of a 100% interest in MindLeap's Digital... Read More...

Mydecine Innovations Group Inc. Signs Partnership Agreement With Applied Pharmaceutical Innovation

VANCOUVER, British Columbia , June 12, 2020 -- Mydecine Innovations Group Inc. (MYCO.CN) (NLBIF) (0NF.F) ("Mydecine"), is pleased to announce the establishment of a research division agreement with Applied Pharmaceutical Innovation ("API"), a translational commercial drug development institute hosted in the University of Alberta's Faculty... Read More...

Newleaf Brands Announces its Move into State-of-the-art 7,500 sq. ft. Specialty Mycology R&D and Product Development Lab in Denver, Colorado

VANCOUVER, British Columbia, June 2, 2020 --  NewLeaf Brands Inc. (CSE: NLB) (OTC: NLBIF) (FSE: 0NF) ("NewLeaf Brands" or the "Company"), soon to put into effect its name change to Mydecine Group, is pleased to announce the completion of its wholly-owned and operated world class R&D Lab and Facilities focused on the mycology of the  f... Read More...

NewLeaf Brands Announces Correction Further to Name and Stock Ticker Symbol Change to Mydecine Innovations Group Inc. (CSE: MYCO)

VANCOUVER, British Columbia , June 1, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") announces correction to its news release dated June 1, 2020 with respect to the effective date of the name and symbol ticker change. The Company disclosed that the name and symbol ticker change to take effect... Read More...

CFN Enterprises Inc. Engaged by MindLeap Health, an Innovative Digital Health Platform in Psychedelics Industry

CFN Enterprises Aims to Capitalize on an Industry That is Projected to Grow at a 16.3% Compound Annual Growth Rate Between 2020 and 2027 to Reach $6.86 Billion, According to Data Bridge Market ResearchSanta Monica, California--(Newsfile Corp. - June 1, 2020) -  CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leadi... Read More...

NewLeaf Brands Announces Name and Stock Ticker Symbol Change to Mydecine Innovations Group Inc. (CSE: MYCO)

VANCOUVER, British Columbia , June 1, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") is pleased to announce that it has changed its name from NewLeaf Brands Inc. to Mydecine Innovations Group Inc. and its ticker symbol from 'NLB' to 'MYCO'. Subject to approval of the Canadian Securities Excha... Read More...

NewLeaf Brands Provides an Update to its Shareholders on Recent Corporate Developments and Shares a Positive Outlook

VANCOUVER, British Columbia , May 28, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") a parent company operating innovative product divisions in the Naturally Sourced Therapies (NST) space, is delighted to provide its shareholders with a review of the recent milestones the Company has reached.... Read More...

Repeat: NewLeaf Brands Announces Newest NewLeaf Brands Advisor Appointee, Dr. Aubrey Oliver, Set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts

VANCOUVER , May 26, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") is pleased to announce that it has officially appointed Dr. Aubrey Oliver ND, RBT to be its newest advisor. Dr. Oliver is a Jamaican registered Functional Holistic doctor and a graduate of Ashford University in Complementary a... Read More...

Newleaf Brands Announces Newest Newleaf Brands Advisor Appointee, Dr. Aubrey Oliver, set to Spearhead Jamaican-based Psilocybin Healing Retreat Efforts

VANCOUVER, British Columbia , May 26, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") is pleased to announce that it has officially appointed Dr. Aubrey Oliver ND, RBT to be its newest advisor. Dr. Oliver is a Jamaican registered Functional Holistic doctor and a graduate of Ashford University ... Read More...

NewLeaf Brands Announces Oversubscription of Brokered Private Placement Led by Canaccord Genuity

VANCOUVER, British Columbia , May 22, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") is pleased to announce that further to the previously announced brokered private placement (the "Offering") being led by Canaccord Genuity Corp. (the "Agent") of up to 6,666,667 units of the Company (the "Uni... Read More...

NewLeaf Brands announces C$2.0 million brokered private placement led by Canaccord Genuity

/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /VANCOUVER , May 21, 2020 - NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf" or the "Company") is pleased to announce that it has entered into an agreement with Canaccord Genuity Corp. (the "Agent") to act as lead age... Read More...

NewLeaf Brands Agrees to Acquire Mindleap Health Inc., Digital Health Platform to Combine Mood, Emotion and Habit Tracking With Tele-health in the Fight Against Mental Illness

VANCOUVER, British Columbia , May 21, 2020 -- NewLeaf Brands Inc. (NLB.CN) (OTC: NLBIF) (0NF.F) ("NewLeaf Brands" or the "Company") is pleased to announce that it has signed a non-binding Letter of Intent ("LOI") with Mindleap Health Inc. ("Mindleap"), dated May 20, 2020 , pursuant to which NewLeaf Brands will acquire, by way of share exc... Read More...
Coming Soon.
SymbolExchangePriceChangeAs of
MYCO.CD
Canadian Securities Exchange - CSE Listed
Canadian Securities Exchange - CSE Listed0.46CAD-1.08%
0NFA.F
Frankfurt Stock Exchange
Frankfurt Stock Exchange0.30EUR-5.66%
MYCOF.PK
US 'Other OTC' and Grey Market
US 'Other OTC' and Grey Market0.37USD--
0NFA.SG
Stuttgart Stock Exchange
Stuttgart Stock Exchange0.31EUR+1.49%
0NFA.D
Dusseldorf Stock Exchange
Dusseldorf Stock Exchange0.30EUR+6.29%
0NFA.MU
Munich Stock Exchange
Munich Stock Exchange0.31EUR0.00%
0NFA.HA
Hanover Stock Exchange
Hanover Stock Exchange0.30EUR+7.80%

Delayed data (1h)


Share this page